TrialAssure launches TrialResults.com TrialAssure, a global software company focused on developing clinical trial transparency tools, has announced the launch of TrialResults.com, a new portal for sponsors to publicly share plain language, or lay, summaries with clinical trial participants. This portal allows trial participants to access the plain language summaries in any region of the world and in their native language.
In place of mailing paper copies of the plain language summaries to participants, sponsors can upload the summary onto the portal.
Using TrialResults.com takes just three steps:
Currently, only 2 percent of clinical trial sponsors have issued plain language summaries to participants in the past few years, as recently reported by Applied Clinical Trials.
“TrialResults.com comes at a crucial time in the pharmaceutical industry when the requirement for posting lay summaries is looming,” said Alan Nicolle, Director, Business Development & Business Alliance Partnerships at TrialAssure in London.
Learn more at www.trialresults.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.